MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Accounts Receivables 2011-2026 | QTNT
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.32 M | 5.4 M | 3.35 M | 2.86 M | 2.56 M | 2.27 M | 1.81 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.4 M | 1.81 M | 3.37 M |
Quarterly Accounts Receivables Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.65 M | 5.18 M | 5.06 M | 6.27 M | 6.15 M | 5 M | 4.45 M | 4.45 M | 4.54 M | 4.54 M | 4.52 M | 5.97 M | 5.04 M | 4.33 M | 4.72 M | 3.35 M | 2.36 M | 2.51 M | 2.88 M | 2.86 M | 2.02 M | 2.46 M | 2.8 M | 2.56 M | 1.64 M | 3.95 M | 2.36 M | 2.27 M | 1.48 M | 2.12 M | 2.21 M | 1.81 M | 2.01 M | 2.65 M | 3.23 M | 2.44 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.65 M | 1.48 M | 3.58 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.17 B | $ 110.24 | -2.87 % | $ 33.5 B |  USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
299 M | - | - | $ 19.8 B | USA |
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Biodesix
BDSX
|
8.6 M | $ 14.21 | -2.67 % | $ 1.84 B | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.01 | -4.74 % | $ 4.62 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 16.36 | -11.57 % | $ 176 M |  China |
 |
Sotera Health Company
SHC
|
139 M | $ 13.13 | -3.03 % | $ 3.73 B | USA |
 |
DarioHealth Corp.
DRIO
|
2.14 M | $ 8.11 | -4.02 % | $ 32.3 M |  Israel |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
BioNano Genomics
BNGO
|
5.2 M | $ 1.16 | 0.87 % | $ 6.32 M | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
1.22 B | $ 62.25 | -5.81 % | $ 24.3 B | USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 23.53 | -4.74 % | $ 654 M | USA |
 |
Charles River Laboratories International
CRL
|
709 M | $ 159.16 | -3.62 % | $ 7.89 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 195.51 | -1.22 % | $ 21.7 B | USA |
 |
Organovo Holdings
ONVO
|
30 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
29.3 K | - | -16.95 % | $ 1.54 M | USA |
 |
Guardant Health
GH
|
138 M | $ 84.61 | -3.96 % | $ 10.6 B | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 102.08 | -0.97 % | $ 8.42 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
552 M | $ 558.32 | -2.61 % | $ 44.9 B | USA |
 |
Illumina
ILMN
|
735 M | $ 117.67 | -5.41 % | $ 18.7 B | USA |
 |
PerkinElmer
PKI
|
783 M | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
96.1 M | - | - | $ 21.2 M | USA |
 |
IQVIA Holdings
IQV
|
3.4 B | $ 163.85 | -3.28 % | $ 28.2 B | USA |
 |
Interpace Biosciences
IDXG
|
8.54 M | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
153 M | $ 8.7 | -4.92 % | $ 1.89 B | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 264.2 | -1.56 % | $ 22 B | USA |
 |
Psychemedics Corporation
PMD
|
3.69 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
1.3 M | $ 25.97 | -4.52 % | $ 33.7 M | USA |
 |
CareDx, Inc
CDNA
|
42.6 M | $ 16.78 | -3.95 % | $ 894 M | USA |
 |
Syneos Health
SYNH
|
729 M | - | - | $ 4.46 B | USA |